FDA panel to review saline implants in March
This article was originally published in Clinica
The US FDA's general and plastic surgery advisory panel will review two PMA applications for saline breast implants on March 1-3. Two Santa Barbara, California, companies, Mentor and Inamed's McGhan Medical, submitted PMAs with extensive clinical data in November to comply with a recent FDA regulation in order to continue selling the popular products.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.